中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

437 records (took 0.034 seconds)

    IMPLANTABLE VITAL SIGN SENSOR
    41.
    发明申请
    IMPLANTABLE VITAL SIGN SENSOR 审中-公开

    公开(公告)号：US20190313923A1

    公开(公告)日：2019-10-17

    申请号：US16453163

    申请日：2019-06-26

    Applicant: Thomas Jefferson University

    Inventor： Jeffrey I JOSEPH

    IPC: A61B5/0215 ,  A61B5/07 ,  A61B5/00 ,  A61B5/1455

    Abstract: An implantable vital sign sensor including a housing including a first portion, the first portion defining a first open end, a second open end opposite the first end, and a lumen there through, the first portion being sized to be implanted substantially entirely within the blood vessel wall of the patient. A sensor module configured to measure a blood vessel blood pressure waveform is included, the sensor module having a proximal portion and a distal portion, the distal portion being insertable within the lumen and the proximal portion extending outward from the first open end.

    PD-L1 and PD-L2-based fusion proteins and uses thereof
    42.
    发明授权
    PD-L1 and PD-L2-based fusion proteins and uses thereof 有权

    公开(公告)号：US10364279B2

    公开(公告)日：2019-07-30

    申请号：US15487539

    申请日：2017-04-14

    Applicant: Thomas Jefferson University

    Inventor： Mark L. Tykocinski

    IPC: C07K14/705 ,  C07K14/525 ,  A61K38/00

    Abstract: Provided are fusion proteins comprising a first domain and a second domain, wherein the first domain comprises a polypeptide that binds to and triggers PD-1 and the second domain comprises a polypeptide that binds to and triggers a TRAIL receptor or Fas. In some embodiments, the polypeptide that binds to and triggers PD-1 comprises at least a portion of the extracellular domain of PD-L1 or PD-L2 and the second domain comprises at least a portion of the extracellular domain of TRAIL or Fas ligand. Also provided are methods for treating autoimmune, alloimmune or inflammatory diseases, and methods for treating cancer, using the fusion proteins.

    Methods of treating a neurodegenerative disease in a mammal in need thereof
    45.
    发明授权
    Methods of treating a neurodegenerative disease in a mammal in need thereof 有权

    公开(公告)号：US10258615B2

    公开(公告)日：2019-04-16

    申请号：US15103234

    申请日：2014-12-09

    Applicant: Thomas Jefferson University

    Inventor： Davide Trotti ,  Piera Pasinelli ,  Michael R. Jablonski

    IPC: A61K31/55 ,  A61K45/06 ,  A61K31/428 ,  A61K31/473 ,  A61K31/496 ,  A61K31/4725

    Abstract: The present invention provides a method of treating or ameliorating a neurodegenerative disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a neurodegenerative disease drug, wherein the drug is a substrate of an ABC transporter inhibitor, wherein the mammal is further administered a therapeutically effective amount of an ABC transporter inhibitor, whereby the neurodegenerative disease is treated in the mammal. In certain embodiments, the neurodegenerative disease comprises at least one selected from the group consisting of spinal cord injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, prion disease, amyotrophic lateral sclerosis, a tauopathy, and chronic traumatic encephalopathy.

    NON-SELECTIVE PROTEASE ACTIVATED RECEPTOR 4 ALA120THR ISOFORM ANTAGONIST
    50.
    发明申请
    NON-SELECTIVE PROTEASE ACTIVATED RECEPTOR 4 ALA120THR ISOFORM ANTAGONIST 审中-公开

    公开(公告)号：US20180297996A1

    公开(公告)日：2018-10-18

    申请号：US15768329

    申请日：2016-10-14

    Applicant: THOMAS JEFFERSON UNIVERSITY

    Inventor： Paul F. Bray

    IPC: C07D471/04 ,  C07D209/12 ,  C07D209/14 ,  C07D401/04 ,  C07D401/14 ,  A61P9/10

    CPC classification number: C07D471/04 ,  A61P9/10 ,  C07D209/12 ,  C07D209/14 ,  C07D401/04 ,  C07D401/14

    Abstract: A substance of Formula (I) for use as a medicament for the treatment of cardiovascular diseases, wherein R is nitrogen or carbon; R1 is selected from the group consisting of a hydrogen, a trifluoromethyl, a methyloxyphenyl, a phenyl, a C1-C3 phenylalkyl, a halogenated phenyl, a halogenated C1-C3 phenylalkyl, a trifluoromethyloxy, a trifluoromethyl oxyphenyl, and a C1-C3 pyridinylalkyl; R2 is selected from the group consisting of a C1-C3 alkyl alcohol optionally substituted with a C1-C3 alkoxyphenyl, a C1-C3 N-alkylmethanamine, a C1-C3 alkoxymethyl, a C1-C3 phenylalkoxymethyl, a C1-C3 cyclopropylalkoxymethyl, and a methoxyethoxymethyl; and R3 is a phenyl or a methoxypyridinyl; and R4 is selected from the group consisting of a hydrogen, a cyano, a C1-C3 sulfonyl, a nitro, and a trifluoromethyl.

Patent Agency Ranking